Trial Profile
Clinicalpharmacological study of 0.0015% DE-085 (tafluprost) ophthalmic solution in healthy adult male volunteers. -ocular blood flow measurements as efficacy endpoints-
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 May 2016
Price :
$35
*
At a glance
- Drugs Tafluprost (Primary) ; Bunazosin
- Indications Glaucoma
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
- 19 May 2016 New trial record